Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The announcement underscores the company’s commitment to advancing its biotech division alongside its mining operations.
Greenland Mines is a Nasdaq-listed company with two operating divisions: mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project, and biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The Canadian patent strengthens Greenland Mines’ position in the gene therapy space, particularly for neurodegenerative diseases that currently have limited treatment options. With KLTO-101 and KLTO-202 moving toward manufacturing, the company is poised to enter the clinical stage, potentially offering new therapies for conditions affecting millions worldwide. For more details, the full press release is available at https://ibn.fm/x2pHAA. Latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the company's SEC filings. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date hereof.
